European Commission approves Gevalka ensartinib for ALK-positive advanced lung cancer

The oral ALK inhibitor has secured final EU authorisation for previously untreated and crizotinib-treated ALK-positive advanced non-small cell lung cancer, following evidence of progression-free survival benefit.
On 16 November 2026, the European Commission granted marketing authorisation to Gevalka (ensartinib), with SFL Pharmaceuticals Deutschland GmbH as marketing authorisation holder, for adults with ALK-positive advanced non-small cell lung cancer.
The approval covers patients who have not previously received an ALK inhibitor and those previously treated with crizotinib, supported by evidence including improved progression-free survival compared with crizotinib in the first-line setting.
Field | Content |
Alert Type | Approval |
Product | Gevalka |
Active Ingredient or Technology | Ensartinib; oral anaplastic lymphoma kinase inhibitor |
Company or Marketing Authorisation Holder | SFL Pharmaceuticals Deutschland GmbH; Betta Pharmaceuticals associated with product development |
Regulatory Authority | European Commission |
Approval Type | Initial centralised European Union marketing authorisation |
Approved Indication | Gevalka monotherapy for ALK-positive advanced non-small cell lung cancer in adults previously untreated with an ALK inhibitor or previously treated with crizotinib |
Patient Population | Adults with ALK-positive advanced non-small cell lung cancer who are ALK-inhibitor-naive or previously treated with crizotinib |
Therapy Area(s) | Oncology; lung cancer; ALK-positive non-small cell lung cancer |
What Was Approved | The European Commission authorised ensartinib as an oral targeted monotherapy for two defined populations of adults with ALK-positive advanced non-small cell lung cancer. |
Supporting Evidence | An open-label randomised active-controlled study demonstrated improved progression-free survival with ensartinib versus crizotinib in the first-line setting. Clinical data also showed relevant tumour response rates after prior crizotinib treatment. |
Clinical Significance | The authorisation adds an oral ALK-targeted treatment option for biomarker-selected patients with advanced non-small cell lung cancer, including those previously treated with crizotinib. |
Regulatory Context | The European Medicines Agency's CHMP issued a positive opinion on 17 September 2026. The European Commission granted final authorisation on 16 November 2026, recorded in the EU Union Register under EU/1/26/2078. |
Key Takeaway | Gevalka has received final EU marketing authorisation for ALK-positive advanced non-small cell lung cancer in both ALK-inhibitor-naive and post-crizotinib adult populations. |
What to Watch | Commercial availability, national pricing and reimbursement decisions, clinical adoption and further evidence on effectiveness and safety in routine practice. |
Primary Source | https://ec.europa.eu/health/documents/community-register/html/reg_last.htm |
Approval Date | 16 November 2026 |
Discover how nuaxia can support your next medical education initiative:
Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector
Contact us on: support@nuaxia.com

Comments